Zenas BioPharma, Inc. (ZBIO) Stock
4 of the hedge funds AlphaScala tracks reported ZBIO in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Millennium Management's at $16.76M.
Which hedge funds own ZBIO?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Millennium Management Israel Englander | 660K | $16.76M | +39% |
| Marshall Wace | 323K | $8.21M | -36% |
| Citadel Ken Griffin | 196K | $4.97M | +193% |
| Point72 Steve Cohen | 16K | $409.5K | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →ZBIO price chart
Powered by TradingViewWhat does Zenas BioPharma, Inc. do?
Zenas BioPharma, Inc. is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of transformative therapies for autoimmune diseases. The company focuses on advancing innovative immunology-based treatments, with a strong commitment to addressing diseases characterized by significant unmet medical needs. Zenas BioPharma's pipeline features lead candidates such as obexelimab, a bifunctional monoclonal antibody targeting CD19 and FcγRIIb, and orelabrutinib, a highly selective Bruton’s Tyrosine Kinase (BTK) inhibitor in Phase 3 development for multiple sclerosis and other autoimmune indications. The firm's portfolio also includes other monoclonal antibodies and immunomodulators under investigation for disorders like immunoglobulin G4-related disease and systemic lupus erythematosus. Guided by values emphasizing innovation, urgency, and patient impact, Zenas BioPharma operates with the aim of bringing novel treatment options to patients, their families, and caregivers, ultimately seeking to improve quality of life and redefine therapeutic possibilities in the autoimmune sector.